KMI
69
-2
YUM
43
-6
HRB
59
2
CSCO
58
-2
R
70
-3
THC
60
-5
AIV
64
4
IR
63
-3
EL
15
-3
ADM
28
3
AN
50
-5
FOX
51
-6
UAL
83
-2
CAH
48
-6
FFIV
66
-4
MRO
50
4
IRM
41
3
SYY
49
9
SJM
9
-5
CI
45
-3
KMI
69
-2
YUM
43
-6
HRB
59
2
CSCO
58
-2
R
70
-3
THC
60
-5
AIV
64
4
IR
63
-3
EL
15
-3
ADM
28
3
AN
50
-5
FOX
51
-6
UAL
83
-2
CAH
48
-6
FFIV
66
-4
MRO
50
4
IRM
41
3
SYY
49
9
SJM
9
-5
CI
45
-3
Financhill
Back

Allogene Therapeutics Quote, Financials, Valuation and Earnings

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
15

ALLO
Allogene Therapeutics

Last Price:
2.27
Seasonality Move:
6.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.

Allogene Therapeutics Price Quote

$2.27

Allogene Therapeutics Key Stats

Sell
15
Allogene Therapeutics (ALLO) is a Sell
Day range:
$2.26 - $2.52
52-week range:
$2.01 - $5.78
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4,806.19
P/B ratio:
1.03%
Volume:
3.1M
Avg. volume:
2.1M
1-year change:
-16.54%
Market cap:
$476M
Revenue:
$95K
EPS:
$-1.56

How Much Does Allogene Therapeutics Make?

Data Unavailable

Is Allogene Therapeutics Growing As A Company?

Data Unavailable

Allogene Therapeutics Stock Price Performance

What Is Allogene Therapeutics 52-Week High & Low?

Allogene Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Allogene Therapeutics?

Is Allogene Therapeutics Cash Flow Positive?

  • What Is ALLO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$217.3M
  • What Is Allogene Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $111.1M
  • What Is Allogene Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $88.2M

Allogene Therapeutics Return On Invested Capital

Data Unavailable

Allogene Therapeutics Earnings Date & Stock Price

Allogene Therapeutics Competitors

  • Who Are Allogene Therapeutics's Competitors?
    Below is a list of companies who compete with Allogene Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • ANI Pharmaceuticals Inc (ANIP)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Protalix BioTherapeutics Inc (PLX)

Allogene Therapeutics Dividend Yield

Allogene Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 17.77%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 9.08
Upside from Last Price: 300.15%

Major Shareholders

  • How many ALLO shares are owned by institutional investors?
    294.9M ALLO shares are owned by institutional investors
  • How many ALLO shares are owned by insiders?
    13.3M ALLO shares are owned by insiders